about
Review of patient-reported outcome measures in chronic hepatitis CStructural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172Hepatitis C virus; its implication for endodontistsAutoimmune thrombocytopenia related to chronic hepatitis C virus infection.Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin.Structural analysis of asunaprevir resistance in HCV NS3/4A proteasePharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms.Phylogenetic analysis of HCV subgenotypes in patients from Sichuan province in China based on the NS5B region.Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies.Improving Viral Protease Inhibitors to Counter Drug Resistance.Hepatitis C Is Poorly Associated With Drug Use in Cambodian Americans in Lowell, Massachusetts.Assessing gene-gene interactions in pharmacogenomics.Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument.Oral conditions associated with hepatitis C virus infection.Antisense antimicrobial therapeuticsIncreased Spontaneous Programmed Cell Death Is Associated with Impaired Cytokine Secretion in Peripheral Blood Mononuclear Cells from Hepatitis C Virus-Positive Patients.Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.Influence of human T-cell lymphotropic virus type 1 (HTLV-1) Infection on laboratory parameters of patients with chronic hepatitis C virus.The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs.Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: Single center real life results.Hepatitis C virus: Morphogenesis, infection and therapy.
P2860
Q26828825-2C4CE28C-6D35-4E66-8E1A-A589458624BBQ27703170-2F663F3E-7662-4CF4-B111-033C69B3E883Q28390336-D2D9A870-2A21-4F63-A260-B9B0C70B2FEFQ33382854-F6292FD3-7AD0-40F9-B043-CE9DF7A8261CQ33394560-4365F464-30CF-4EAF-9298-BF71DC2BE51BQ34576194-C7CAD819-7D11-43F1-9514-29649A46B3B6Q35205520-01059EC0-83E7-4326-AD55-AAF01FF40C98Q36041672-E2FA0243-F393-44CA-8365-38348C1FA81CQ36890411-15E8B08C-7C03-4690-93A5-45D8FA2394FDQ37017282-0D14F592-AE9C-484A-ADC6-93C676041554Q37091589-F2A2D190-841D-4850-B080-E4B36F10CD8FQ37986775-7239E46B-87C8-421D-ACB2-CB827296AF5FQ38134312-51747472-DD7B-4B5A-B5C7-88816A2679B8Q38160291-1DEC1CB4-6E7E-4F19-8709-1BF2A05C18C4Q38885150-331D554A-0E15-427E-B460-EDF7FFE12C98Q40287814-3D70EA46-EC1D-4DEB-A3DC-C990CF353C8EQ42276983-A67EDC8C-51D6-4560-908E-C0CF9A2931A7Q42995255-92FA92CC-F927-4101-9779-3FA8397B3316Q45374021-51E3D7A3-0BE0-4865-A244-D25696069798Q52622829-47A33147-63F3-488F-B9DF-984DEBCDA143Q52661702-640DA78A-5CA6-4AF7-B959-6AC8CB0AA553
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Hepatitis C: a clinical review
@ast
Hepatitis C: a clinical review
@en
Hepatitis C: a clinical review
@nl
type
label
Hepatitis C: a clinical review
@ast
Hepatitis C: a clinical review
@en
Hepatitis C: a clinical review
@nl
prefLabel
Hepatitis C: a clinical review
@ast
Hepatitis C: a clinical review
@en
Hepatitis C: a clinical review
@nl
P2860
P3181
P1433
P1476
Hepatitis C: a clinical review
@en
P2093
P2860
P3181
P356
10.1111/J.1601-0825.2007.01419.X
P577
2008-01-01T00:00:00Z